$FEMY

Mifek Jeffrey Gerald purchased $10K of FEMY

Mifek Jeffrey Gerald (Chief Clinical-Medical Affairs) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Mifek Jeffrey Gerald
Published Aug 12, 2026, 12:54 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FEMY
Bullish
low confidence
Mentioned
$FEMY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYBullishLow
01

Why it matters

The only new fact is the reported open-market purchase by an officer; there is no accompanying company news (earnings, trial results, approvals, contracts, or guidance).

02

Market read

Traders may note mild sentiment from insider buying, but the disclosure is unlikely to drive a material repricing without additional company catalysts.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still lacks context on motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11 for a 2026-08-07 purchase

Background

This is an SEC Form 4 insider transaction disclosure for FEMASYS Inc (FEMY).

Company-level read

Ticker impact

$FEMYBullishLow confidence
Context

Form 4 shows officer Mifek Jeffrey Gerald bought 3,125 shares of FEMASYS Inc at $3.20 on 2026-08-07, totaling $10,000.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The transaction size is modest ($10k) and the filing does not include new operational or financial guidance, clinical, or regulatory developments.

Market effects

No sector read-through is provided beyond a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or tax/portfolio-driven, especially at small dollar amounts, and may not signal improved prospects.

Key entities

  • FEMASYS INC

    Company whose insider transaction was disclosed on Form 4.

  • Mifek Jeffrey Gerald

    Chief Clinical-Medical Affairs officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.